Terns Pharmaceuticals said on Tuesday it will stop developing its experimental obesity drug after a mid-stage trial showed modest weight loss and raised safety concerns.

Celcuity expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025. Click here to ...

According to new data, 73% of all participants in treatment courts did not commit another felony offense within five years of ...

Democratic-led states secured a legal victory to keep the personal data of food recipients out of the federal government's ...

The B.S. degree launched this fall as part of a long-term plan that began in 2017 with local industry approaching UNLV to ...

The partnership will enable NetApp and the 49ers Foundation to utilize the unique setting of Levi's® Stadium to provide ...

The discussion will feature a panel of distinguished experts in biodiversity conservation, data analytics, business, and ...

In President Donald Trump’s America, information that has been relied on for decades to make critical decisions has been ...

As the Washington Data Exchange for Public Safety publishes for the first time data on police use of force incidents, ...

The imbalance between energy supply and demand driven by data centers is the leading cause of your skyrocketing electricity ...

Whether your chip is running a vintage computer game or the latest DeepSeek model, it’ll reward you for speaking its native ...

But pretending problems don’t exist won’t make them go away. The ostrich approach is no way to solve U.S. hunger or any other ...